385785-02-4

Basic information

• Product Name: 2-AMINO-4-(BENZYLOXY)-5-METHOXYBENZONITRILE
• Synonyms: 2-AMINO-4-(BENZYLOXY)-5-METHOXYBENZONITRILE
• CAS NO: 385785-02-4
• Molecular Formula: C₁₅H₁₄N₂O₂
• Molecular Weight: 254.28
• Mol File: 385785-02-4.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-AMINO-4-(BENZYLOXY)-5-METHOXYBENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4-(BENZYLOXY)-5-METHOXYBENZONITRILE(385785-02-4)
• EPA Substance Registry System: 2-AMINO-4-(BENZYLOXY)-5-METHOXYBENZONITRILE(385785-02-4)

Safety Data

• Hazardous Substances Data: 385785-02-4(Hazardous Substances Data)

Usage

General Description

2-AMINO-4-(BENZYLOXY)-5-METHOXYBENZONITRILE is a chemical compound with the molecular formula C15H14N2O2. It is a benzodinitrile derivative with an amino group, a methoxy group and a benzyloxy group attached to a benzene ring. 2-AMINO-4-(BENZYLOXY)-5-METHOXYBENZONITRILE is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. It has potential applications in the field of medicinal chemistry and drug development. Additionally, it may also have uses in the production of dyes and other organic materials. The compound’s unique structure and properties make it a valuable building block in the chemical industry.

Upstream product

• 52805-46-6 2-methoxy-5-cyanophenol 
• 4421-08-3 3-methoxy-4-hydroxybenzonitrile 
• 100-39-0 benzyl bromide 
• 52805-34-2 4-(benzyloxy)-3-methoxybenzonitrile 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 385784-84-9 4-(benzyloxy)-5-methoxy-2-nitrobenzonitrile 

Downstream Products

• 60771-18-8 7-(benzyloxy)-2,4-dichloro-6-methoxyquinazoline 
• 723283-25-8 (E)-tert-butyl 4-((4-cyano-5-(((dimethylamino)methylene)amino)-2-methoxyphenoxy)methyl)piperidine-1-carboxylate 
• 443913-73-3 vandetanib 
• 338992-12-4 N-Desmethylvandetanib 
• 338992-20-4 4-(((4-((4-bromo-2-fluorophenyl)amino)-6-methoxyquinazolin-7-yl)oxy)methyl)piperidine-1-carboxylic acid tert-butyl ester 
• 1320288-64-9 2-cyclohexyl-7-(2-(2-(dimethylamino)ethoxy)ethoxy)-N-(1-isopropylpiperidin-4-yl)-6-methoxyquinazolin-4-amine 
• 1320288-63-8 2-cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine 
• 1320288-42-3 C₂₃H₃₄N₄O₂ 
• 1255580-76-7 2-cyclohexyl-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine 
• 1320288-41-2 7-(benzyloxy)-2-cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxyquinazolin-4-amine 
• 1320288-39-8 7-(benzyloxy)-4-chloro-2-cyclohexyl-6-methoxyquinazoline 
• 1320288-38-7 7-(benzyloxy)-2-cyclohexyl-6-methoxyquinazolin-4(3H)-one 
• 385785-03-5 N'-(5-benzyloxy-2-cyano-4-methoxy-phenyl)-N,N-dimethylformamidine 
• 723278-14-6 di-tert-butyl {1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1,3-thiazol-2-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl}methyl phosphate 

Relevant articles and documents

An alternative synthesis of Vandetanib (Caprelsa) via a microwave accelerated Dimroth rearrangement

Vandetanib is an orally available tyrosine kinase inhibitor used in the treatment of cancer. The current synthesis proceeds via an unstable 4-chloroquinazoline, using harsh reagents, in addition to requiring sequential protection and deprotection steps. In the present work, use of the Dimroth rearrangement in the key quinazoline forming step enabled the synthesis of Vandetanib in nine steps (compared to the previously reported 12–14).

Identification and Structure–Activity Relationship Studies of Small-Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1

The methyllysine reader protein Spindlin1 has been implicated in the tumorigenesis of several types of cancer and may be an attractive novel therapeutic target. Small-molecule inhibitors of Spindlin1 should be valuable as chemical probes as well as potential new therapeutics. We applied an iterative virtual screening campaign, encompassing structure- and ligand-based approaches, to identify potential Spindlin1 inhibitors from databases of commercially available compounds. Our in silico studies coupled with in vitro testing were successful in identifying novel Spindlin1 inhibitors. Several 4-aminoquinazoline and quinazolinethione derivatives were among the active hit compounds, which indicated that these scaffolds represent promising lead structures for the development of Spindlin1 inhibitors. Subsequent lead optimization studies were hence carried out, and numerous derivatives of both lead scaffolds were synthesized. This resulted in the discovery of novel inhibitors of Spindlin1 and helped explore the structure–activity relationships of these inhibitor series.

COMPOUNDS AND COMPOSITIONS USED TO EPIGENETICALLY TRANSFORM CELLS AND METHODS RELATED THERETO

This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, the disclosure contemplates inducing cells, such as adult somatic cells or cells that are not naturally pluripotent, into cells with chemically induce pluripotency. In certain embodiments, the disclosure contemplates certain compounds disclosed herein, compounds disclosed herein optionally substituted with one or more substituents, derivatives, or salts thereof, for these purposes.